Jean Mancini, MD
Internal Medicine · Bristol, TNNPI 1013914308
Payments from drug & device makers
Across 95 payments — averaging $17.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$265
- Bayer$241
- Johnson & Johnson$142
- Daiichi Sankyo Inc.$115
- AstraZeneca$115
- Amgen$93
- plus $651 from 24 others
What the payments were for
- Food & beverage$1,622100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 18 | $265 |
| Bayer | 14 | $241 |
| Johnson & Johnson | 11 | $142 |
| Daiichi Sankyo Inc. | 5 | $115 |
| AstraZeneca | 6 | $115 |
| Amgen(2 entities) | 5 | $93 |
| Lundbeck LLC | 2 | $51 |
| Novartis | 3 | $50 |
| Calliditas Therapeutics US Inc. | 2 | $49 |
| Pfizer | 3 | $48 |
| Otsuka America Pharmaceutical, Inc. | 2 | $38 |
| GSK | 2 | $37 |
| Inogen, Inc. | 2 | $37 |
| Eisai Inc. | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $32 |
| Mallinckrodt Hospital Products Inc. | 1 | $26 |
| AbbVie | 2 | $25 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $23 |
| Lilly USA, LLC | 1 | $23 |
| Biogen | 1 | $22 |
| Travere Therapeutics, Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $16 |
| OPKO Pharmaceuticals, LLC | 1 | $16 |
| Corium, LLC | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $13 |
| Almatica Pharma LLC | 1 | $13 |
| Kyowa Kirin, Inc. | 1 | $13 |
| Scilex Pharmaceuticals Inc. | 1 | $12 |
How this compares
$1,622 in reported general payments places this provider in the 75th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 79 | $60,190 |
| OzempicSemaglutide | 44 | $52,460 |
| JardianceEmpagliflozin | 23 | $28,705 |
| TrulicityDulaglutide | 27 | $25,976 |
| RexultiBrexpiprazole | 15 | $25,562 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $21,429 |
| XareltoRivaroxaban | 13 | $18,087 |
| FarxigaDapagliflozin Propanediol | 16 | $15,947 |
| LinzessLinaclotide | 15 | $9,230 |
| NexiumEsomeprazole Magnesium | 12 | $6,498 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $6,242 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $5,221 |
| BelsomraSuvorexant | 11 | $4,608 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 232 | $4,451 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $3,439 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $48 | $60,19079 claims |
| Novo NordiskOzempic | $265 | $52,46044 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $18 | $34,94835 claims |
| Lilly USA, LLCTrulicity | $23 | $25,97627 claims |
| AstraZenecaFarxiga, Nexium, Symbicort | $115 | $25,88441 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $38 | $25,56215 claims |
| GSKTrelegy Ellipta | $37 | $21,42933 claims |
| Johnson & JohnsonXarelto | $142 | $18,08713 claims |
| AbbVieLinzess | $25 | $9,23015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Bristol
- Bernard GrunstraBristol$6.4M
- Rick WhilesBristol$1.5M
- Donald QuinnBristol$868K
- Stephanie PowellBristol$170K
- Shelby OldsBristol$89K
- Mark McKenzieChattanooga$11.9M
- Jewel WhiteKingsport$5.7M
- Judith WhiteKingsport$5.6M
- Obadias MarquezOoltewah$2.8M
- Amanda Moore MillerKnoxville$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.